Literature DB >> 35429381

Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine.

Mathieu Le Gars1, Jerald Sadoff1, Frank Struyf2, Dirk Heerwegh2, Carla Truyers2, Jenny Hendriks1, Glenda Gray3, Beatriz Grinsztejn4, Paul A Goepfert5, Hanneke Schuitemaker1, Macaya Douoguih1.   

Abstract

This secondary analysis of the phase 3 ENSEMBLE trial (NCT04505722) assessed the impact of preexisting humoral immunity to adenovirus 26 (Ad26) on the immunogenicity of Ad26.COV2.S-elicited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody levels in 380 participants in Brazil, South Africa, and the United States. Among those vaccinated in Brazil and South Africa, 31% and 66%, respectively, had prevaccination serum-neutralizing activity against Ad26, with little preexisting immunity detected in the United States. Vaccine recipients in each country had similar postvaccination spike (S) protein-binding antibody levels, indicating that baseline immunity to Ad26 has no clear impact on vaccine-induced immune responses.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Entities:  

Keywords:  Ad26.COV2.S; COVID-19; SARS-CoV-2; preexisting immunity; vaccine

Mesh：

Substances：

Year:  2022        PMID： 35429381      PMCID： PMC9047246          DOI： 10.1093/infdis/jiac142

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   7.759


  11 in total

1.  Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors.

Authors:  Mieke C Sprangers; Wandena Lakhai; Wouter Koudstaal; Marielle Verhoeven; Björn F Koel; Ronald Vogels; Jaap Goudsmit; Menzo J E Havenga; Stefan Kostense
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

2.  A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine.

Authors:  Nadine C Salisch; Kathryn E Stephenson; Kristi Williams; Freek Cox; Leslie van der Fits; Dirk Heerwegh; Carla Truyers; Marrit N Habets; Diane G Kanjilal; Rafael A Larocca; Peter Abbink; Jinyan Liu; Lauren Peter; Carlos Fierro; Rafael A De La Barrera; Kayvon Modjarrad; Roland C Zahn; Jenny Hendriks; Conor P Cahill; Maarten Leyssen; Macaya Douoguih; Johan van Hoof; Hanneke Schuitemaker; Dan H Barouch
Journal:  Ann Intern Med       Date:  2021-02-16       Impact factor: 25.391

3.  Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).

Authors:  Dan H Barouch; Frank L Tomaka; Frank Wegmann; Daniel J Stieh; Galit Alter; Merlin L Robb; Nelson L Michael; Lauren Peter; Joseph P Nkolola; Erica N Borducchi; Abishek Chandrashekar; David Jetton; Kathryn E Stephenson; Wenjun Li; Bette Korber; Georgia D Tomaras; David C Montefiori; Glenda Gray; Nicole Frahm; M Juliana McElrath; Lindsey Baden; Jennifer Johnson; Julia Hutter; Edith Swann; Etienne Karita; Hannah Kibuuka; Juliet Mpendo; Nigel Garrett; Kathy Mngadi; Kundai Chinyenze; Frances Priddy; Erica Lazarus; Fatima Laher; Sorachai Nitayapan; Punnee Pitisuttithum; Stephan Bart; Thomas Campbell; Robert Feldman; Gregg Lucksinger; Caroline Borremans; Katleen Callewaert; Raphaele Roten; Jerald Sadoff; Lorenz Scheppler; Mo Weijtens; Karin Feddes-de Boer; Daniëlle van Manen; Jessica Vreugdenhil; Roland Zahn; Ludo Lavreys; Steven Nijs; Jeroen Tolboom; Jenny Hendriks; Zelda Euler; Maria G Pau; Hanneke Schuitemaker
Journal:  Lancet       Date:  2018-07-06       Impact factor: 79.321

Review 4.  Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.

Authors:  Jerome Custers; Denny Kim; Maarten Leyssen; Marc Gurwith; Frank Tomaka; James Robertson; Esther Heijnen; Richard Condit; Georgi Shukarev; Dirk Heerwegh; Roy van Heesbeen; Hanneke Schuitemaker; Macaya Douoguih; Eric Evans; Emily R Smith; Robert T Chen
Journal:  Vaccine       Date:  2020-10-03       Impact factor: 3.641

5.  Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.

Authors:  Jerald Sadoff; Mathieu Le Gars; Georgi Shukarev; Dirk Heerwegh; Carla Truyers; Anne M de Groot; Jeroen Stoop; Sarah Tete; Wim Van Damme; Isabel Leroux-Roels; Pieter-Jan Berghmans; Murray Kimmel; Pierre Van Damme; Jan de Hoon; William Smith; Kathryn E Stephenson; Stephen C De Rosa; Kristen W Cohen; M Juliana McElrath; Emmanuel Cormier; Gert Scheper; Dan H Barouch; Jenny Hendriks; Frank Struyf; Macaya Douoguih; Johan Van Hoof; Hanneke Schuitemaker
Journal:  N Engl J Med       Date:  2021-01-13       Impact factor: 91.245

6.  Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.

Authors:  Zacchaeus Anywaine; Houreratou Barry; Omu Anzala; Gaudensia Mutua; Sodiomon B Sirima; Serge Eholie; Hannah Kibuuka; Christine Bétard; Laura Richert; Christine Lacabaratz; M Juliana McElrath; Stephen C De Rosa; Kristen W Cohen; Georgi Shukarev; Michael Katwere; Cynthia Robinson; Auguste Gaddah; Dirk Heerwegh; Viki Bockstal; Kerstin Luhn; Maarten Leyssen; Rodolphe Thiébaut; Macaya Douoguih
Journal:  PLoS Med       Date:  2022-01-11       Impact factor: 11.069

7.  Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.

Authors:  Houreratou Barry; Gaudensia Mutua; Hannah Kibuuka; Zacchaeus Anywaine; Sodiomon B Sirima; Nicolas Meda; Omu Anzala; Serge Eholie; Christine Bétard; Laura Richert; Christine Lacabaratz; M Juliana McElrath; Stephen De Rosa; Kristen W Cohen; Georgi Shukarev; Cynthia Robinson; Auguste Gaddah; Dirk Heerwegh; Viki Bockstal; Kerstin Luhn; Maarten Leyssen; Macaya Douoguih; Rodolphe Thiébaut
Journal:  PLoS Med       Date:  2021-10-29       Impact factor: 11.069

8.  Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.

Authors:  Jerald Sadoff; Glenda Gray; An Vandebosch; Vicky Cárdenas; Georgi Shukarev; Beatriz Grinsztejn; Paul A Goepfert; Carla Truyers; Ilse Van Dromme; Bart Spiessens; Johan Vingerhoets; Jerome Custers; Gert Scheper; Merlin L Robb; John Treanor; Martin F Ryser; Dan H Barouch; Edith Swann; Mary A Marovich; Kathleen M Neuzil; Lawrence Corey; Jeffrey Stoddard; Karin Hardt; Javier Ruiz-Guiñazú; Mathieu Le Gars; Hanneke Schuitemaker; Johan Van Hoof; Frank Struyf; Macaya Douoguih
Journal:  N Engl J Med       Date:  2022-02-09       Impact factor: 176.079

9.  Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.

Authors:  Lindsey R Baden; Daniel J Stieh; Michal Sarnecki; Stephen R Walsh; Georgia D Tomaras; James G Kublin; M Juliana McElrath; Galit Alter; Guido Ferrari; David Montefiori; Philipp Mann; Steven Nijs; Katleen Callewaert; Paul Goepfert; Srilatha Edupuganti; Etienne Karita; Johannes P Langedijk; Frank Wegmann; Lawrence Corey; Maria G Pau; Dan H Barouch; Hanneke Schuitemaker; Frank Tomaka
Journal:  Lancet HIV       Date:  2020-10       Impact factor: 12.767

10.  Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.

Authors:  Feng-Cai Zhu; Xu-Hua Guan; Yu-Hua Li; Jian-Ying Huang; Tao Jiang; Li-Hua Hou; Jing-Xin Li; Bei-Fang Yang; Ling Wang; Wen-Juan Wang; Shi-Po Wu; Zhao Wang; Xiao-Hong Wu; Jun-Jie Xu; Zhe Zhang; Si-Yue Jia; Bu-Sen Wang; Yi Hu; Jing-Jing Liu; Jun Zhang; Xiao-Ai Qian; Qiong Li; Hong-Xing Pan; Hu-Dachuan Jiang; Peng Deng; Jin-Bo Gou; Xue-Wen Wang; Xing-Huan Wang; Wei Chen
Journal:  Lancet       Date:  2020-07-20       Impact factor: 202.731
View more
  1 in total

1.  A Single Oral Immunization with Replication-Competent Adenovirus-Vectored Vaccine Induces a Neutralizing Antibody Response in Mice against Canine Distemper Virus.

Authors:  Xiang Du; Emeline Goffin; Lucie Gillard; Bénédicte Machiels; Laurent Gillet
Journal:  Viruses       Date:  2022-08-23       Impact factor: 5.818
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.